China emerging as 'major player' for pharmaceuticals
China wants to become a major developer of vaccines for the developing world.
The pharmaceuticals industry is starting to take much more notice of China, as the country emerges as a major developer of vaccines for the developing world.
China's drugs industry is close to being given the go ahead to manufacture the Japanese encephalitis vaccine for the developing world.
According to the British Medical Journal, this will mark it out as a "major new player" in the market.
Seth Berkley, chief executive of the GAVI Alliance, believes that Chinese drugs firms will be ready by the start of next year for the World Health Organization (WHO) to carry out pre-qualifications inspections of production of the vaccine.
There has been a push for contract services with Asia in recent times, thanks to the region's growing presence in the pharma market.
China's rise is likely to further facilitate the establishment of outsourcing agreements between the west and Asia, once it has the processes in place to develop such vaccines on a mass scale to WHO requirements.
Once the WHO checks have been carried out, the UN will be able to purchase the vaccine for countries without their own regulatory systems.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...